<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.02">
 <iati-activity hierarchy="1" iati-activities:version="2.02" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>XM-DAC-903-SII-38095</iati-identifier>
  <reporting-org ref="XM-DAC-903" type="40">
   <narrative xml:lang="EN">International Finance Corporation</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Granules III</narrative>
  </title>
  <description type="2">
   <narrative xml:lang="EN">The Project will significantly demonstrate how domestic companies use their strong comparative advantages of low cost of production, scale, quality and regulatory compliance to exploit the opportunities that enable them to move up the pharmaceutical value chain in selling to more regulated markets. The Project will support the Company&apos;s expansion enabling wider availability of high quality, low cost drugs in developed and developing markets.</narrative>
  </description>
  <description type="1">
   <narrative xml:lang="EN">table, .k-table{ border-collapse:collapse; width:100%; table-layout:fixed; margin-bottom: 15px;} .k-table, .k-table td, table, table td {outline: 0;border: 1px solid #000; } .k-table td, table td { padding: 5px; }           Granules India Limited (Granules or the Company)  an existing IFC client - is an Indian pharmaceutical company engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs) of a variety of drugs, including over-the-counter ones. The Company sells its products mainly in the US, Europe, Latin America and India.         Granules has wholly-owned manufacturing plants near Hyderabad in India (Jeedimetla, Bonthapally, and Gagillapur) and in Vishakhapatnam, India along with a R&amp;D and manufacturing facility in Virginia, USA Further, through its joint ventures, it  &#xA0;&#xA0;   has one plant in China and yet another manufacturing plant in Vishakhapatnam, India. .         The Company is undertaking an investment program directed towards setting up new capacity, expanding existing capacities and investing in R&amp;D to improve its product mix in favor of higher value-added products. A large part of the investment program is in the form of capital expenditures in India (the Project), which is estimated to cost about US$84 million. The Project includes building a greenfield API manufacturing facility in Vishakhapatnam, India, expanding existing API and PFI capacities, investment in R&amp;D, quality assurance (&quot;QA), and quality control(&quot;QC), investment &#xA0;    in other general capital expenditures at existing facilities,    &#xA0;   and additional warehouse capacity.</narrative>
  </description>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">GRANULES INDIA LIMITED</narrative>
  </participating-org>
  <participating-org activity-id="XM-DAC-903-SII-38095" ref="XM-DAC-903" role="1" type="40"></participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2017-03-31" type="1"></activity-date>
  <activity-date iso-date="2017-04-13" type="2"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">International Finance Corporation</narrative>
   </organisation>
   <telephone>+12024733800</telephone>
   <email>ccspg@ifc.org</email>
   <website>www.ifc.org</website>
   <mailing-address>
    <narrative xml:lang="EN">2121 Pennsylvania Avenue, NW Washington DC 20433</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="2">
   <mailing-address>
    <narrative xml:lang="EN">Granules India Ltd.  Mr. BVRK Srinivas  AVP Formulations  +918418255233  srinivas.bvrk@granulesindia.com  Granules India Limited, Plot No. 160/A &amp; 161/E,, Gagillapur Village, Qutubullapur Mandal, RR Distric  www.granulesindia.com</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="2">
   <mailing-address>
    <narrative xml:lang="EN">table, .k-table{ border-collapse:collapse; width:100%; table-layout:fixed; margin-bottom: 15px;} .k-table, .k-table td, table, table td {outline: 0;border: 1px solid #000; } .k-table td, table td { padding: 5px; }         Mr.R.Ramraj, AVP - Formulations       Address:  &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;        Granules India Limited      Plot No. 160/A &amp; 161/E,      Gagillapur Village,      Qutubullapur Mandal,      RR District - 500 043      &#xA0;      Tel: +91 8418 3066 6400       Email id:  &#xA0;   Ramraj.r@granulesindia.com         Local access of project documentation         The Company will disclose this ESRS and ESAP locally at the following address:         Mr.P.N.Baskaran, AVP-Operations (API)        Granules India Limited        Temple Road, Bonthapally Village, Jinnaram Mandal, Medal Dist.         Tel: +91 8458- 306600        Email id:    Baskaran.pn@granulesindia.com            Plot No. 166/A &amp; 161/E Gagillapur Village,         Qutubullapur Mandal,         RR District  500 043        Tel: +91-040-2309 6942        &#xA0;        Contact for Vizag projects        Mr. Vedprakash&#xA0;S. Ragate, VP - Manufacturing (Operations)        Plot No.30, JN Pharma City, Parawada Mandal,        Visakapatnam, Andhra Pradesh-530019        Tel: +91-08924 236696        &#xA0;        &#xA0;        &#xA0;        &#xA0;        And on its website: www.granulesindia.com</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="IN" percentage="100">
   <narrative xml:lang="EN">India</narrative>
  </recipient-country>
  <location ref="IN-India">
   <location-reach code="1"></location-reach>
   <location-id code="1453782" vocabulary="G1"></location-id>
   <name>
    <narrative xml:lang="EN">table, .k-table{ border-collapse:collapse; width:100%; table-layout:fixed; margin-bottom: 15px;} .k-table, .k-table td, table, table td {outline: 0;border: 1px solid #000; } .k-table td, table td { padding: 5px; }        The greenfield API capacity will be set up at Vishakhapatnam, India whereas the rest of the Project will be executed across the Companys various facilities.</narrative>
   </name>
   <description>
    <narrative xml:lang="EN">Location description</narrative>
   </description>
   <activity-description>
    <narrative xml:lang="EN">A description that qualifies the activity taking place at the location.</narrative>
   </activity-description>
   <administrative code="1453782" level="1" vocabulary="G1"></administrative>
   <point srsName="http://www.opengis.net/def/crs/EPSG/0/4326">
    <pos>22.0000000000 79.0000000000</pos>
   </point>
   <exactness code="2"></exactness>
   <location-class code="1"></location-class>
   <feature-designation code="ADMF"></feature-designation>
  </location>
  <sector code="325" percentage="100" vocabulary="11" vocabulary-uri="http://www.census.gov/cgi-bin/sssd/naics/naicsrch?chart=2012">
   <narrative xml:lang="EN">G-FA - Pharmaceuticals and Medicine Manufacturing</narrative>
  </sector>
  <country-budget-items vocabulary="1">
   <budget-item code="7.2.1" percentage="100" vocabulary="1">
    <description>
     <narrative xml:lang="EN">Total: $47.71 million</narrative>
    </description>
   </budget-item>
  </country-budget-items>
  <collaboration-type code="6"></collaboration-type>
  <default-flow-type code="35"></default-flow-type>
  <default-finance-type code="411"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget type="1">
   <period-start iso-date="2017-03-31"></period-start>
   <period-end iso-date="2017-06-30"></period-end>
   <value currency="USD" value-date="2017-03-31">47710000</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2017-03-31"></transaction-date>
   <value currency="USD" value-date="2017-03-31">47710000</value>
   <receiver-org>
    <narrative xml:lang="EN">GRANULES INDIA LIMITED</narrative>
   </receiver-org>
   <flow-type code="35"></flow-type>
   <finance-type code="411"></finance-type>
  </transaction>
  <document-link format="TEXT/HTML" url="https://disclosures.ifc.org/project-detail/SII/38095/granules-iii">
   <title>
    <narrative xml:lang="EN">Summary of Investment Information - Anticipated Impact Measurement &amp; Monitoring (AIMM) Assessment and Main Environmental &amp; Social Risks and Impacts of the Project</narrative>
   </title>
   <category code="A01"></category>
   <language code="EN"></language>
  </document-link>
  <document-link format="TEXT/HTML" url="https://disclosures.ifc.org/project-detail/SII/38095/granules-iii">
   <title>
    <narrative xml:lang="EN">Summary of Investment Information</narrative>
   </title>
   <category code="A12"></category>
   <language code="EN"></language>
  </document-link>
 </iati-activity>
</iati-activities>
